CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Research Foundation of State University of New York v. Lupin Limited

1:09-cv-00483

Overview

Case Number 1:09-cv-00483
Filing Date 2009-07-02
Status Terminated
Termination Date 2012-02-06
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand Defendant

Parties

Defendant

New York University NPE (University / Research)

Represented By

2 Attorneys Listed

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Thomas Francis Driscoll , III

Bifferato LLC

Tel: +1 (302) 225-7600

Bifferato LLC, 800 N. King Street

Lupin Limited NPE (University / Research)

Represented By

2 Attorneys Listed

Counter Claimant

Lupin Pharmaceuticals Inc. Operating Company

Represented By

2 Attorneys Listed

Counter Defendant

Galderma Laboratories Inc. Operating Company

Represented By

1 Attorneys Listed

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Research Foundation of State University of New York NPE (University / Research)

Represented By

1 Attorneys Listed

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Galderma Laboratories LP NPE (Individual / Inventor)

Represented By

1 Attorneys Listed

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts 5 proceedings
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (5 found):
U.S. Courts: 5
U.S. District Court 2016-10-27
1:16-cv-01003

Galderma Laboratories, L.P. v. Sun Pharmaceutical Industries Limited

U.S. Family Sibling (["US7211267", "US7749532", "US8206740", "US8394405", "US8394406", "US8470364", "US8709478", "US7232572", "US8603506", "US9241946"])
Status: DED
U.S. District Court 2016-03-31
1:16-cv-00207

Galderma Laboratories L.P. v. Amneal Pharmaceuticals LLC

U.S. Family Sibling (["US7211267", "US7749532", "US8206740", "US8394405", "US8394406", "US8470364", "US8709478", "US7232572", "US8603506", "US9241946"])
Status: DED
U.S. District Court 2011-11-08
1:11-cv-01106

Galderma Laboratories Inc. v. Amneal Pharmaceuticals LLC

U.S. Family Sibling (["US7749532", "US7232572", "US7211267", "US8206740"])
Status: DED
U.S. District Court 2009-09-18
1:09-cv-00703

Research Foundation of State University of New York v. Impax Laboratories Inc.

Asserted Patent
Status: DED
U.S. District Court 2009-03-19
1:09-cv-00184

Research Foundation of State University of New York v. Mylan Pharmaceuticals Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7232572
Methods of treating rosacea
Filed: 2005-02-18
Issued: 2007-06-19
Expired (Term Ended)
Expires: 2025-02-18
US7211267
Methods of treating acne
Filed: 2002-04-05
Issued: 2007-05-01
Expired (Term Ended)
Expires: 2022-04-05
US5789395
Method of using tetracycline compounds for inhibition of endogenous nitric oxide production
Filed: 1996-08-30
Issued: 1998-08-04
Expired (Term Ended)
Expires: 2016-08-30
US5919775
Method for inhibiting expression of inducible nitric oxide synthase with tetracycline
Filed: 1998-04-16
Issued: 1999-07-06
Expired (Term Ended)
Expires: 2018-04-16

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, injunctive relief is barred.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(50 total)
Pleading / Complaint

COMPLAINT filed against Lupin Pharmaceuticals Inc., Lupin Limited - Magistrate Consent Notice to Pltf. ( Filing fee $ 350, receipt number 03110000000000604770.) - filed by Research Foundation of State University of New York, New York University, Galderma Laboratories Inc., Galderma Laboratories LP. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Civil Cover Sheet)(dzs, ) (Entered: 07/06/2009)

Entry #1 • 2009-07-02
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (dzs, ) (Entered: 07/06/2009)

Entry #2 • 2009-07-02
1

Disclosure Statement pursuant to Rule 7.1 filed by Research Foundation of State University of New York. (dzs, ) (Entered: 07/06/2009)

Entry #3 • 2009-07-02
1

Disclosure Statement pursuant to Rule 7.1 filed by New York University. (dzs, ) (Entered: 07/06/2009)

Entry #4 • 2009-07-02
1

Disclosure Statement pursuant to Rule 7.1 filed by Galderma Laboratories Inc. identifying Corporate Parent Galderma Pharma SA for Galderma Laboratories Inc. (dzs, ) Modified on 7/6/2009 (dzs, ). (Entered: 07/06/2009)

Entry #5 • 2009-07-02
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc